Abstract
We have examined the effects of nicotine pre-treatment on mesoprefrontal dopamine (DA) function in the presence and absence of acute stress, and the involvement of endogenous opiate peptide systems (EOPS). Acute electrical footshock stress preferentially increases DA utilization in medial prefrontal cortex (mPFC) compared to nucleus accumbens (NAS) and striatal terminal fields, and this is correlated with profound locomotor immobility. Our recent studies have demonstrated that repeated, but not acute, nicotine pre-treatment significantly reduced mPFC DA utilization and footshock stress-induced immobility responses. There is increasing evidence that the biochemical and behavioral effects of nicotine are mediated by EOPS, and we hypothesized that the stress-reducing effects of repeated nicotine administration in these studies were mediated by EOPS. Accordingly, rats pre-treated subcutaneously with repeated nicotine were given a single dose of the opiate receptor antagonist naloxone (0.1–10.0 mg/kg, i.p.) or saline as a co-treatment with nicotine or saline 10 min prior to acute footshock stress. Naloxone had no effects on non-stressed or acute footshock stress-induced mPFC DA utilization, but dose-dependently antagonized repeated nicotine's attenuation of stress-induced mesoprefrontal DA utilization and immobility responses. Furthermore, naloxone dose-dependently blocked repeated nicotine's augmentation of accumbal DA utilization. These results suggest that EOPS may be involved in mediating repeated nicotine administration effects on mesoprefrontal dopaminergic and immobility responses to acute footshock stress.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Aceto MD, Scates SM, Ji Z, Bowman ER . (1993): Nicotine's opioid and anti-opioid interactions: proposed role in smoking behavior. Eur J Pharmacol 248: 333–335
Balfour DJK, Fagerstrom KO . (1996): Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Pharmacol Ther 72: 51–81
Boyd RT . (1997): The molecular biology of neuronal nicotinic acetylcholine receptors. Crit Rev Toxicol 27: 299–318
Christensen M-K, Smith DF . (1990): Antinociceptive effects of the stereoisomers of nicotine given intrathecally in spinal rats. J Neural Transm 80: 189–194
Corrigall WA, Herling S, Coen KM . (1988): Evidence for opioid mechanisms in the behavioral effects of nicotine. Psychopharmacology 96: 29–35
Davenport KE, Houdi AA, Van Loon GR . (1990): Nicotine protects against μ-opioid receptor antagonism by β-funaltrexamine: Evidence for nicotine-induced release of endogenous opiods in the brain. Neurosci Lett 113: 40
Davis M, Astrachan DI . (1978): Conditioned fear and startle magnitude: Effects of different footshock or barshock intensities used in training. J Exp Psychol 4: 95–103
Devine DP, Leone P, Pocock D, Wise RA . (1993): Differential involvement of ventral tegmental mu, delta, and kappa opioid receptors in modulation of basal mesolimbic dopamine release: In vivo microdialysis studies. J Pharmacol Exp Ther 244: 1067–1080
Eiden LE, Giraud P, Dave JT, Hotchkiss AJ, Affolter H . (1984): Nicotinic receptor stimulation activates enkephalin release and biosynthesis in adrenal chromaffin cell. Nature 312: 661
Elsworth JD, Brittan MS, Taylor JR, Sladek JR, Al-Tikriti MS, Zea-Ponce Y, Innis RB, Redmond DE Jr, Roth RH . (1996): Restoration of dopamine transporter density in the striatum of fetal ventral mesencephalon-grafted, but not sham-grafted, MPTP-treated parkinsonian monkeys. Cell Transpl 5: 315–325
Finley JCW, Maderdrut JL, Petrusz P . (1981): The immunocytochemical localization of enkephalin in the central nervous system of the rat. J Comp Neurol 198: 541–565
George TP, Verrico CD, Roth RH . (1997): Effects of nicotine and stress on rat mesoprefrontal dopamine systems: Evidence for opiate mechanisms. Soc Neurosci Abstr 23: 1359
George TP, Verrico CD, Roth RH . (1998): Effects of repeated nicotine pre-treatment on mesoprefrontal dopaminergic and behavioral responses to acute footshock stress. Brain Res 801: 36–49
Gorelick DA, Rose J, Jarvik ME . (1988): Effects of naloxone on cigarette smoking. J Subst Abuse 1: 153–159
Henningfield JE, Schuh LM, Jarvik ME . (1995): Pathophysiology of tobacco dependence. In: Bloom FE, Hupfer DJ (eds), Psychopharmacology: The Fourth Generation of Progress. New York, Raven Press, pp 1715–1729
Hildebrand BE, Nomikos GG, Bondjers C, Nisell M, Svensson TH . (1997): Behavioral manifestations of the nicotine abstinence syndrome in the rat: Peripheral versus central mechanisms. Psychopharmacology 129: 348–356
Hildebrand BE, Nomikos GG, Panagis G, Hertel P, Schilstrom B, Svensson TH . (1998): Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. Brain Res 779: 214–225
Horger BA, Roth RH . (1996): The role of mesoprefrontal dopamine neurons in stress. Crit Rev Neurobiol 10: 395–418
Houdi AA, Pierzchala K, Marson M, Palkovits M, Van Loon GR . (1991): Nicotine-induced alteration in Tyr-Gly-Gly and Met-enkephalin in discrete brain nuclei reflects altered enkephalin neuron activity. Peptides 12: 161
Kalivas PW, Abhold R . (1987): Enkephalin release into the ventral tegmental area in response to stress: Modulation of mesocorticolimbic dopamine. Brain Res 414: 339–348
Karras A, Kane JM . (1980): Naloxone reduces cigarette smoking. Life Sci 27: 1541–1545
Khachaturian H, Lewis ME, Watson SJ . (1983): Enkephalin systems in diencephalon and brainstem of the rat. J Comp Neurol 220: 310–320
Krishnan-Sarin S, Rosen MI, O'Malley SS . (1999): Evidence for an opioid component in nicotine dependence. Arch Gen Psychiatry 56: 663–668
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ . (1957): Protein measurement with the phenol-folin reagent. J Biol Chem 193: 265–275
Malin DH, Lake JR, Carter VA, Cunningham JS, Wilson OB . (1993): Naloxone precipitates nicotine abstinence syndrome in the rat. Psychopharmacology 112: 339–342
Malin DH, Lake JR, Payne MC, Short PE, Carter VA, Cunningham JS, Wilson OB . (1996a): Nicotine alleviation of nicotine abstinence syndrome is naloxone-reversible. Pharmacol Biochem Behav 53: 81–85
Malin DH, Lake JR, Short PE, Blossman JB, Lawless BA, Schopen CK, Sailer EE, Burgess K, Wilson OB . (1996b): Nicotine abstinence syndrome precipiated by an analog of neuropeptide FF. Pharmacol Biochem Behav 54: 581–585
McGehee DS, Role LW . (1995): Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Ann Rev Physiol 57: 521–546
Miller JD, Speciale SG, McMillen BA, German DC . (1984): Naloxone antagonism of stress-induced augmentation of frontal cortex dopamine metabolism. Eur J Pharmacol 98: 437–439
Nemeth-Coslett R, Griffiths RR . (1986): Naloxone does not affect cigarette smoking. Psychopharmacology 89: 261–264
Nisell M, Nomikos GG, Hertel P, Panagis G, Svennson TH . (1996): Condition-independent sensitization of locomotor stimulation and mesocortical dopamine release following chronic nicotine treatment in the rat. Synapse 22: 369–381
O'Malley SS, Krishnan-Sarin S, Meandzija B . (1997): Naltrexone treatment of nicotine dependence: A preliminary study. Presented at the Annual Meeting of the American Psychiatric Association, San Diego, CA, May 1997.
Paxinos G, Watson C . (1986): The Rat Brain in Stereotaxic Coordinates, 2nd ed. San Diego, CA, Academic Press
Pidoplichko VI, DeBias M, Williams JT, Dani JA . (1997): Nicotine activates and desensitizes midbrain dopamine neurons. Nature 390: 401–404
Pomerleau OF, Fertig JB, Seyler LE, Jaffe J . (1983): Neuroendocrine reactivity to nicotine in smokers. Psychopharmacology 81: 61–67
Sesack SR, Pickel VM . (1992): Dual ultrastructural localization of enkephalin and tyrosine hydroxylase immunoreactivity in the rat ventral tegmental area: Multiple substrates for opiate-dopamine interactions. J Neurosci 12: 1335–1350
Shieh K-R, Pan J-T . (1997): Nicotinic control of tuberoinfundibular dopaminergic neuron activity and prolactin secretion: Diurnal rhythm and involvement of endogenous opiodergic system. Brain Res 756: 266–272
Spanagel R, Herz A, Shippenberg TS . (1992): Opposing tonically active endogenous opiate systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci USA 89: 2046–2050
Sutherland G, Stapleton JA, Russell MA, Feyerabend C . (1995): Naltrexone, smoking behavior and cigarette withdrawal. Psychopharmacology 120: 418–425
Tam S-Y . (1988): Regulation of Mesoprefrontal Dopamine Neurons. Ph.D. Thesis. New Haven, CT, Yale University
Thierry AM, Tassin J-P, Blanc G, Glowinski J . (1976): Selective activation of the mesocortical dopamine system by stress. Nature 263: 2420–2424
Vezina P, Blanc G, Glowinski J, Tassin J-P . (1992): Nicotine and morphine differentially activate brain dopamine in prefrontocortical and subcortical terminal fields: Effects of acute and repeated injections. J Pharmacol Exp Ther 261: 484–490
Zarrindast M-R, Farzin D . (1996): Nicotine attenuates naloxone-induced jumping behavior in morphine-dependent mice. Eur J Pharmacol 298: 1–6
Acknowledgements
This study was supported in part by a Lucille P. Markey Physician-Scientist Award and a NARSAD Young Investigator Award (TPG) and USPHS Grants K12-DA00167 (to TPG) and MH-14092 (to RHR). We thank Jane R. Taylor, Ph.D., Suchitra Krishnan-Sarin, Ph.D., and Marina R. Picciotto, Ph.D. for their helpful comments on the manuscript.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
George, T., Verrico, C., Xu, L. et al. Effects of Repeated Nicotine Administration and Footshock Stress on Rat Mesoprefrontal Dopamine Systems: Evidence for Opioid Mechanisms. Neuropsychopharmacol 23, 79–88 (2000). https://doi.org/10.1016/S0893-133X(99)00165-7
Received:
Revised:
Accepted:
Issue date:
DOI: https://doi.org/10.1016/S0893-133X(99)00165-7
